



Biocon Biologics in Saudi Arabia: Factsheet

Biocon Biologics is a leading global biosimilars company committed to addressing patients' needs for cost-effective, high-quality biosimilars.

VISION

To be a global leader in biologics, delivering affordable access to innovative and inclusive healthcare solutions, transforming patients' lives.

VALUES

- Innovation & differentiation
- Quality through compliance & best practices
- Integrity and ethical behaviour
- Collaboration, teamwork and mutual respect
- Performance-driven culture

Company Profile

Biocon Biologics is present in over 120 countries globally, including more than 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.

In the Africa-Middle East (AFMET) region, Biocon Biologics is making a significant impact on patients' lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 6 commercialized biosimilars.

Saudi Arabia is among the key focus countries for Biocon Biologics in the AFMET region, where biosimilars adoption is steadily increasing. The company's integrated insulin manufacturing and R&D facility in Malaysia, the largest in Asia, manufactures a broad portfolio of regular, basal, and rapid-acting insulins to address the need for affordable insulins in AFMET and other markets worldwide.

Through its self-led and partner-led commercial models, the company is focused on broadening access to biosimilars for treating cancer, diabetes and autoimmune disease for the benefit of patients and improving healthcare outcomes in Saudi Arabia.

Bengaluru-headquartered Biocon Biologics has a longstanding presence in the biosimilars industry, having invested over \$1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner Viatris has further strengthened Biocon Biologics' commercial presence in Saudi Arabia. As a trusted and reliable company, Biocon Biologics is poised to consolidate its leadership in biosimilars in Saudi Arabia, making a meaningful impact on patients' lives.

The Biocon Biologics Advantage

- **PATIENT-CENTRICITY:** Dedicated to expanding patient reach and generating significant savings for patients, payers, and healthcare systems.
- **LAB-TO-MARKET EXPERTISE:** Fully integrated from biosimilars development to manufacturing, distribution, and commercialization.
- **LEGACY OF SUCCESS:** Achieved several industry firsts with U.S. approvals for biosimilar Trastuzumab, biosimilar Pegfilgrastim, and interchangeable biosimilar Insulin Glargine.
- **UNIQUE PORTFOLIO:** A comprehensive and differentiated portfolio of biosimilars, including insulins, monoclonal antibodies, and conjugated recombinant proteins.
- **GLOBAL SCALE PRODUCTION:** Operates three large-scale, globally compliant biosimilars manufacturing facilities, ranking among the top 15* companies worldwide in biomanufacturing capacity.
- **WIDE COMMERCIAL FOOTPRINT:** Commercialized products in 120+ countries through a combination of direct presence, strategic partnerships, and distributors.
- **HIGH QUALITY & COMPLIANCE STANDARDS:** Manufacturing facilities have received 80+ cGMP approvals from over 25 agencies, including the U.S. FDA and EMA.

*19th Annual Report of BioPlan Associates

Our Products in Saudi Arabia

Brand Name	Molecule
Ogivri ^	Trastuzumab
Krabeva #	Bevacizumab
Fulphila ^	Pegfilgrastim
Neucyte #	Pegfilgrastim
Semglee **	Insulin Glargine
Hulio *	Adalimumab
Nepexto *	Etanercept

* Hulio and Nepexto are commercialized by our partner Boston Oncology in Saudi Arabia

** Semglee is commercialized by our partner Al Rajhi Pharma in Saudi Arabia

Krabeve and Neucyte are distributed by our partner Jamjoom Medical Co. in Saudi Arabia

^ Ogivri and Fulphila are distributed by our partner Cigalah in Saudi Arabia

Biocon Biologics in Saudi Arabia

Business Partnership

Souhail Tebib
Head of AFMET-CIS
souhail.tebib@biocon.com

Prasanth Manghat
Assistant General Manager,
Commercial, AFMET
prasanth.manghat@biocon.com

Susheel Umesh
Chief Commercial Officer,
Emerging Markets
Email: susheel.umesh@biocon.com


Media

Seema Ahuja
Global Head of Corporate Brand & Head
of Communications – EMs
Email: seema.ahuja@biocon.com

Adverse Events

Email:
npc.drug@sfd.gov.sa

QUICK FACTS



4A Model of Enabling Health Equity

- **Affordability:** Rationalizing treatment costs while improving healthcare outcomes.
- **Availability:** Ensuring reliable product supplies across Advanced and Emerging Markets.
- **Accessibility:** Maximizing patient reach through country-specific self and partner-led commercial models.
- **Assurance:** Establishing a trustworthy brand that stands for the highest global quality.

Global Portfolio

Trastuzumab	Insulin Glargine
Bevacizumab	Insulin Aspart
Pegfilgrastim	Adalimumab
rh-Insulin	Etanercept

For more information:
Biocon Biologics Corporate Factsheet
Website: <https://www.bioconbiologics.com>

